InvestorsHub Logo
Followers 0
Posts 7
Boards Moderated 0
Alias Born 06/08/2017

Re: None

Friday, 06/16/2017 5:29:47 AM

Friday, June 16, 2017 5:29:47 AM

Post# of 256
Oppenheimer upgraded Neuroderm Ltd (NASDAQ: NDRM) from Perform to Outperform with a price target of $42.00, sees as potential takeover.

"While the asset still faces a certain level of clinical and regulatory risk, we believe ND0612 is becoming sufficiently de-risked at this point to attract a potential M&A suitor. Our view is supported by recent reports stating that NDRM has retained a financial advisor for the possible sale of the company, according to Bloomberg."

https://www.streetinsider.com/Analyst+Comments/Oppenheimer+Upgrades+Neuroderm+Ltd+%28NDRM%29+to+Outperform%3B+Alleged+Takeover+Discussions+Pump+New+Life+into+ND0612/13009512.html